Glutaraldehyde-Modified Recombinant Fel d 1: A Hypoallergen With Negligible Biological Activity but Retained Immunogenicity

Background Recombinant allergens are under investigation for replacing allergen extracts in immunotherapy. Site-directed mutagenesis has been suggested as a strategy to develop hypoallergenic molecules that will reduce the risk of side effects. For decades, chemically modified allergen extracts have...

Full description

Bibliographic Details
Main Authors: Serge A. Versteeg, BSc, Ingrid Bulder, BSc, Martin Himly, PhD, Toni M. van Capel, BSc, R. van den Hourt, PhD, Stef J. Koppelman, PhD, Esther C. de Jong, PhD, Fatima Ferreira, PhD, Ronald van Ree, PhD
Format: Article
Language:English
Published: Elsevier 2011-01-01
Series:World Allergy Organization Journal
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455119304296
id doaj-4198442143cd4b4186ba538458a7900d
record_format Article
spelling doaj-4198442143cd4b4186ba538458a7900d2020-11-24T23:49:10ZengElsevierWorld Allergy Organization Journal1939-45512011-01-0147113120Glutaraldehyde-Modified Recombinant Fel d 1: A Hypoallergen With Negligible Biological Activity but Retained ImmunogenicitySerge A. Versteeg, BSc0Ingrid Bulder, BSc1Martin Himly, PhD2Toni M. van Capel, BSc3R. van den Hourt, PhD4Stef J. Koppelman, PhD5Esther C. de Jong, PhD6Fatima Ferreira, PhD7Ronald van Ree, PhD8Department of Experimental Immunology, Academic Medical Center, Amsterdam, The NetherlandsDepartment of Immunopathology, Sanquin Research, Amsterdam, The NetherlandsDepartment of Molecular Biology, University of Salzburg, Salzburg, AustriaDepartment of Cell Biology and Histology, Academic Medical Center, Amsterdam, The NetherlandsR&D Department, HAL Allergy, Leiden, The NetherlandsR&D Department, HAL Allergy, Leiden, The NetherlandsDepartment of Cell Biology and Histology, Academic Medical Center, Amsterdam, The NetherlandsDepartment of Molecular Biology, University of Salzburg, Salzburg, AustriaDepartment of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands; Department of Otorhinolaryngology, Academic Medical Center, Amsterdam, The Netherlands; Corresponding author.Background Recombinant allergens are under investigation for replacing allergen extracts in immunotherapy. Site-directed mutagenesis has been suggested as a strategy to develop hypoallergenic molecules that will reduce the risk of side effects. For decades, chemically modified allergen extracts have been used for the same reason.Aim To evaluate whether glutaraldehyde modification is a good strategy to produce hypoallergenic recombinant allergens with retained immunogenicity.Methods Fel d 1 was cloned as a single construct linking both chains of the molecule and expressed in Escherichia coli and Pichia pastoris. After physicochemical purification, recombinant (r) Fel d 1 was chemically modified using glutaraldehyde. The effect of modification on immune reactivity was evaluated using radioallergosorbent test, CAP inhibition, competitive radioimmunoassay, enzyme-linked immunosorbent assay, basophil histamine release, and T-cell proliferation assays. Both natural and recombinant unmodified Fel d 1 were used as controls.Results rFel d 1 demonstrated similar IgE binding and biologic activity as its natural counterpart. Upon modification, IgE-binding potency decreased >1000-fold, translating into a >106-fold reduction in biologic activity assessed by basophil histamine release. In contrast, the modified recombinant did not show a decreased but even a moderately increased capacity (1.5-fold) to stimulate proliferation of T cells (P < 0.01). Finally, it induced specific IgG antibodies in rabbits that recognized the unmodified allergen.Conclusions Chemical modification is a practical and highly effective approach for achieving hypoallergenicity of recombinant allergens with retained immunogenicity. Keywords: allergoid, Felis domesticus, hypoallergen, immunotherapy, rFel d 1http://www.sciencedirect.com/science/article/pii/S1939455119304296
collection DOAJ
language English
format Article
sources DOAJ
author Serge A. Versteeg, BSc
Ingrid Bulder, BSc
Martin Himly, PhD
Toni M. van Capel, BSc
R. van den Hourt, PhD
Stef J. Koppelman, PhD
Esther C. de Jong, PhD
Fatima Ferreira, PhD
Ronald van Ree, PhD
spellingShingle Serge A. Versteeg, BSc
Ingrid Bulder, BSc
Martin Himly, PhD
Toni M. van Capel, BSc
R. van den Hourt, PhD
Stef J. Koppelman, PhD
Esther C. de Jong, PhD
Fatima Ferreira, PhD
Ronald van Ree, PhD
Glutaraldehyde-Modified Recombinant Fel d 1: A Hypoallergen With Negligible Biological Activity but Retained Immunogenicity
World Allergy Organization Journal
author_facet Serge A. Versteeg, BSc
Ingrid Bulder, BSc
Martin Himly, PhD
Toni M. van Capel, BSc
R. van den Hourt, PhD
Stef J. Koppelman, PhD
Esther C. de Jong, PhD
Fatima Ferreira, PhD
Ronald van Ree, PhD
author_sort Serge A. Versteeg, BSc
title Glutaraldehyde-Modified Recombinant Fel d 1: A Hypoallergen With Negligible Biological Activity but Retained Immunogenicity
title_short Glutaraldehyde-Modified Recombinant Fel d 1: A Hypoallergen With Negligible Biological Activity but Retained Immunogenicity
title_full Glutaraldehyde-Modified Recombinant Fel d 1: A Hypoallergen With Negligible Biological Activity but Retained Immunogenicity
title_fullStr Glutaraldehyde-Modified Recombinant Fel d 1: A Hypoallergen With Negligible Biological Activity but Retained Immunogenicity
title_full_unstemmed Glutaraldehyde-Modified Recombinant Fel d 1: A Hypoallergen With Negligible Biological Activity but Retained Immunogenicity
title_sort glutaraldehyde-modified recombinant fel d 1: a hypoallergen with negligible biological activity but retained immunogenicity
publisher Elsevier
series World Allergy Organization Journal
issn 1939-4551
publishDate 2011-01-01
description Background Recombinant allergens are under investigation for replacing allergen extracts in immunotherapy. Site-directed mutagenesis has been suggested as a strategy to develop hypoallergenic molecules that will reduce the risk of side effects. For decades, chemically modified allergen extracts have been used for the same reason.Aim To evaluate whether glutaraldehyde modification is a good strategy to produce hypoallergenic recombinant allergens with retained immunogenicity.Methods Fel d 1 was cloned as a single construct linking both chains of the molecule and expressed in Escherichia coli and Pichia pastoris. After physicochemical purification, recombinant (r) Fel d 1 was chemically modified using glutaraldehyde. The effect of modification on immune reactivity was evaluated using radioallergosorbent test, CAP inhibition, competitive radioimmunoassay, enzyme-linked immunosorbent assay, basophil histamine release, and T-cell proliferation assays. Both natural and recombinant unmodified Fel d 1 were used as controls.Results rFel d 1 demonstrated similar IgE binding and biologic activity as its natural counterpart. Upon modification, IgE-binding potency decreased >1000-fold, translating into a >106-fold reduction in biologic activity assessed by basophil histamine release. In contrast, the modified recombinant did not show a decreased but even a moderately increased capacity (1.5-fold) to stimulate proliferation of T cells (P < 0.01). Finally, it induced specific IgG antibodies in rabbits that recognized the unmodified allergen.Conclusions Chemical modification is a practical and highly effective approach for achieving hypoallergenicity of recombinant allergens with retained immunogenicity. Keywords: allergoid, Felis domesticus, hypoallergen, immunotherapy, rFel d 1
url http://www.sciencedirect.com/science/article/pii/S1939455119304296
work_keys_str_mv AT sergeaversteegbsc glutaraldehydemodifiedrecombinantfeld1ahypoallergenwithnegligiblebiologicalactivitybutretainedimmunogenicity
AT ingridbulderbsc glutaraldehydemodifiedrecombinantfeld1ahypoallergenwithnegligiblebiologicalactivitybutretainedimmunogenicity
AT martinhimlyphd glutaraldehydemodifiedrecombinantfeld1ahypoallergenwithnegligiblebiologicalactivitybutretainedimmunogenicity
AT tonimvancapelbsc glutaraldehydemodifiedrecombinantfeld1ahypoallergenwithnegligiblebiologicalactivitybutretainedimmunogenicity
AT rvandenhourtphd glutaraldehydemodifiedrecombinantfeld1ahypoallergenwithnegligiblebiologicalactivitybutretainedimmunogenicity
AT stefjkoppelmanphd glutaraldehydemodifiedrecombinantfeld1ahypoallergenwithnegligiblebiologicalactivitybutretainedimmunogenicity
AT esthercdejongphd glutaraldehydemodifiedrecombinantfeld1ahypoallergenwithnegligiblebiologicalactivitybutretainedimmunogenicity
AT fatimaferreiraphd glutaraldehydemodifiedrecombinantfeld1ahypoallergenwithnegligiblebiologicalactivitybutretainedimmunogenicity
AT ronaldvanreephd glutaraldehydemodifiedrecombinantfeld1ahypoallergenwithnegligiblebiologicalactivitybutretainedimmunogenicity
_version_ 1725483744893075456